Patient Blood Management - Use and Outcome

Hemorrhage Clinical Trial

— PBM-USZ  

Official title:

Patient Blood Management - Use and Outcome

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02473666
• Other study ID #: KEK 2015-0175
• Status: Completed
• Start date: January 2012
• Est. completion date: December 2019

Study information

• Verified date: November 2020
• Source: University of Zurich
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Study the influence of transfusion related Patient Blood Management Program actions on transfusion-related outcome measures and cost.

Description:

At the University Hospital of Zurich, an in-house designed monitoring and feedback system was introduced which electronically registers each transfusion of any allogeneic blood product, be it red blood cells, plasma or platelets as well as corresponding laboratory data. Results are reported quarterly to Department heads. The investigator analyzes whether the introduction of this monitoring and feedback system as part of a patient blood management Program has a significant influence on use of allogeneic blood product transfusions and transfusion-related costs, without compromising patient outcome.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 250000
• Est. completion date: December 2019
• Est. primary completion date: December 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Only case records, all discharged patients of the University Hospital of Zürich

Exclusion Criteria:

• Not discharged from our Hospital.

Related Conditions & MeSH terms

• Hemorrhage

Locations

Country	Name	City	State
Switzerland	University Hospital Zurich	Zurich

Sponsors (1)

Lead Sponsor	Collaborator
University of Zurich

Country where clinical trial is conducted

Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of transfusions per participant	Participant wich had transfusion will be identified and the administrative, financial and clinical data will be compared to participants without transfusions	participants will be followed form date of hospital entry until date of discharge or date of death up to 3 years
Secondary	Percentage of transfusion of any blood product per participant	Count of any blood products per case, QM Data	participants will be followed form date of hospital entry until date of discharge or date of death up to 3 years
Secondary	Cost of any blood product per participant	costs per case	participants will be followed form date of hospital entry until date of discharge or date of death up to 3 years
Secondary	Survey of Patient Blood Management System	clinical, financial,and administrative data of all participants will be reviewed on the focus on transfusions	participants will be followed form date of hospital entry until date of discharge or date of death up to 3 years